

Supplemental Table 3. Commonly Reported TEAEs ($\geq 5\%$ of Patients in Either Group or $\geq 3\%$ of Patients With a GI Disorder) Categorized by White Patients

System Organ Class (Preferred Term, MedDRA 19.1)	Lubiprostone 12 mcg BID (n=43), n (%)	Lubiprostone 24 mcg BID (n=25), n (%)	Total (N=68), N (%)
Patients with ≥ 1 TEAE	27 (62.8)	13 (52.0)	40 (58.8)
Gastrointestinal disorders	12 (27.9)	8 (32.0)	20 (29.4)
Diarrhea	5 (11.6)	3 (12.0)	8 (11.8)
Vomiting	3 (7.0)	3 (12.0)	6 (8.8)
Nausea	4 (9.3)	1 (4.0)	5 (7.4)
Abdominal pain upper	1 (2.3)	1 (4.0)	2 (2.9)
Dyspepsia	2 (4.7)	0 (0.0)	2 (2.9)
Abdominal pain	0 (0.0)	1 (4.0)	1 (1.5)
Aphthous ulcer	0 (0.0)	1 (4.0)	1 (1.5)
Infections and infestations	8 (18.6)	3 (12.0)	11 (16.2)
Pharyngitis streptococcal	3 (7.0)	1 (4.0)	4 (5.9)
Investigations	10 (23.3)	6 (24.0)	16 (23.5)
Blood iron decreased	3 (7.0)	2 (8.0)	5 (7.4)
Blood cholesterol increased	0 (0.0)	2 (8.0)	2 (2.9)

BID = twice daily; GI = gastrointestinal; MedDRA = Medical Dictionary for Regulatory Activities; N = total population; n = subgroup of total population; TEAE = treatment-emergent adverse event.